Advertisement

Topics

Samsung Bioepis and Takeda Sign Strategic Agreement

06:50 EDT 21 Aug 2017 | PharmPro

Samsung Bioepis and Takeda sign strategic collaboration agreement to co-develop multiple novel biologic therapies. The immediate program focus is on TAK-671, a therapeutic candidate intended to address unmet need in severe acute pancreatitis.
Contributed Author: 
Samsung Bioepis Co., Ltd.

Original Article: Samsung Bioepis and Takeda Sign Strategic Agreement

NEXT ARTICLE

More From BioPortfolio on "Samsung Bioepis and Takeda Sign Strategic Agreement"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...